Related Experiment Video

Updated: May 13, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.4K

Exploring SGLT2 Inhibitors' Activity in Breast Cancer: An Overview

Ritesh P Bhole1,2, Gayatri S Maldhure1, Harshad S Kapare1

  • 1Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, 411018, India.

Current Topics in Medicinal Chemistry
|April 15, 2025
PubMed

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors show promise in treating breast cancer by inducing apoptosis and altering cancer cell glucose uptake. Further clinical studies are needed to confirm their safety and efficacy.

Area of Science:

  • Oncology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors, primarily used for diabetes, are emerging as potential breast cancer therapeutics.
  • Their mechanisms involve inducing cancer cell apoptosis and reducing glucose uptake.

Purpose of the Study:

  • To investigate the anticancer effects of SGLT2 inhibitors on breast cancer cells.
  • To explore their synergistic potential with conventional chemotherapy.
  • To review their role in breast cancer treatment and precision medicine.

Main Methods:

  • In vitro and in vivo testing of four SGLT2 inhibitors: dapagliflozin, ipragliflozin, canagliflozin, and empagliflozin.
  • Analysis of effects on apoptosis, glucose uptake, and key signaling pathways (PI3K/AKT/mTOR, MAPK).
  • Examination of synergistic effects with chemotherapy agents.

Main Results:

  • SGLT2 inhibitors demonstrated ability to induce apoptosis and reduce glucose uptake in breast cancer cells.
  • Modulation of PI3K/AKT/mTOR and MAPK signaling pathways was observed.
  • Potential for synergistic effects with conventional chemotherapy was indicated.

Conclusions:

  • SGLT2 inhibitors represent a promising therapeutic avenue for breast cancer, impacting key cancer cell processes.
  • Further clinical trials are essential to establish safety and efficacy in breast cancer patients.
  • Integration with precision medicine strategies may enhance treatment outcomes.
Keywords:
SGLT2 (sodium‒glucose cotransporter 2) inhibitorsbreast cancercanagliflozindapagliflozinempagliflozin.ipragliflozin

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.6K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.2K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
141
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.6K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
134
Selectins01:25

Selectins

Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.2K